Synthesis and characterization of bacteriochlorin loaded magnetic nanoparticles (MNP) for personalized MRI guided photosensitizers delivery to tumor

Ostroverkhov, Petr; Semkina, Alevtina S.; Naumenko, Victor; Plotnikova, Еkaterina А.; Melnikov, Pavel; Abakumova, Tatiana O.; Yakubovskaya, Raisa I.; Миронов, А. Ф.; Vodopyanov, Stepan S.; Abakumov, Artem M.; Majouga, Alexander G.; Grin, Mikhail A.; Chekhonin, V. P.; Abakumov, Maxim

doi:10.1016/j.jcis.2018.10.087

Cited by 31 publications

(14 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The hydrodynamic size of MNP-HSA@PS was 83.1 ± 0.6 nm. A detailed characterization of MNP-HSA@PS physical and chemical properties was described previously [28].…”

Section: Resultsmentioning

confidence: 99%

“…Also, high MR contrasting is important to identify precisely drug accumulation peak in tumors. We have previously described theranostic system for PDT, combining bacteriochlorine a and iron oxide nanoparticle coated with HSA [28,29]. Based on in vitro properties it has been hypothesized that the MNP-HSA@PS can be used to identify therapeutic window for PDT and to inhibit tumor growth.…”

Section: Discussionmentioning

confidence: 99%

“…Immobilization was carried out according previously described method [28]. Briefly, PS was dissolved in DMSO.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

HSA—Coated Magnetic Nanoparticles for MRI-Guided Photodynamic Cancer Therapy

et al. 2018

View full text Add to dashboard Cite

Background: Photodynamic therapy (PDT) is a promising technique for cancer treatment; however, low tissue permeability for irradiating light and insufficient photosensitizer (PS) accumulation in tumors limit its clinical potential. Nanoparticles are engineered to improve selective drug delivery to tumor sites, but its accumulation is highly variable between tumors and patients. Identifying PS accumulation peak in a personalized manner is crucial for therapeutic outcome. Magnetic nanoparticles (MNPs) provide opportunity for tracking drug accumulation in dynamics using non-invasive magnetic resonance imaging (MRI). The purpose of the study was to evaluate MNP loaded with PS as a theranostic tool for treating cancer in mice xenograft colon cancer models. Methods: MNPs coated with human serum albumin (HSA) were loaded with bacteriochlorine a. MRI, atomic emission spectroscopy (AES) and fluorescent imaging were used to study MNP and drug accumulation rates and dynamics in CT26 tumors. Tumor growth curves were evaluated in animals that received PDT at different time points upon MNP systemic injection. Results: Peak MNP accumulation in tumors was detected by MRI 60 min post injection (pi) and the data were verified by AES and fluorescent imaging. Up to 17% of injected dose/g of tissue was delivered to malignant tissues 24 h after injection. Consistent with MRI predicted drug accumulation peak PDT performed 60 min after intravenous injection was more efficient in inhibiting tumor growth than treatment scheduled 30 min and 240 min pi. Conclusions: PS loading on HAS-coated MNPs is a perspective approach to increase drug delivery to tumor site. Tracking for MNP accumulation by MRI can be used to predict drug concentration peak in tumors and to adjust PDT time scheduling for improved antitumor response.

show abstract

“…The hydrodynamic size of MNP-HSA@PS was 83.1 ± 0.6 nm. A detailed characterization of MNP-HSA@PS physical and chemical properties was described previously [28].…”

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

HSA—Coated Magnetic Nanoparticles for MRI-Guided Photodynamic Cancer Therapy

et al. 2018

View full text Add to dashboard Cite

show abstract

“…[ 19 ] Numerous articles have reported that MNPs can increase the T2 images of MRI. [ 19 , 29 ] Exosome‐conjugated magnetic NPs can be guided by a magnetic field to become enriched in the brain, and the particles can be detected by mouse cranial MRI. Through in vivo MRI of intracranial GBM, the GBM location was determined and NP signals were observed in T2‐weighted signal (Figure S26 , Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

Synchronous Disintegration of Ferroptosis Defense Axis via Engineered Exosome‐Conjugated Magnetic Nanoparticles for Glioblastoma Therapy

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is one of the most fatal central nervous system tumors and lacks effective or sufficient therapies. Ferroptosis is a newly discovered method of programmed cell death and opens a new direction for GBM treatment. However, poor blood–brain barrier (BBB) penetration, reduced tumor targeting ability, and potential compensatory mechanisms hinder the effectiveness of ferroptosis agents during GBM treatment. Here, a novel composite therapeutic platform combining the magnetic targeting features and drug delivery properties of magnetic nanoparticles with the BBB penetration abilities and siRNA encapsulation properties of engineered exosomes for GBM therapy is presented. This platform can be enriched in the brain under local magnetic localization and angiopep‐2 peptide‐modified engineered exosomes can trigger transcytosis, allowing the particles to cross the BBB and target GBM cells by recognizing the LRP‐1 receptor. Synergistic ferroptosis therapy of GBM is achieved by the combined triple actions of the disintegration of dihydroorotate dehydrogenase and the glutathione peroxidase 4 ferroptosis defense axis with Fe3O4 nanoparticle‐mediated Fe2+ release. Thus, the present findings show that this system can serve as a promising platform for the treatment of glioblastoma.

show abstract

“…Moreover, some SPIONs have been clinically approved as contrast agents: ferumoxytol (30nm), ferumoxides (120-180nm), ferucarbotran(60nm), ferristene (diameter not less than 300nm) and ferumoxsil (300nm) [48] . Recent studies continue to investigate the use of MNPs as MRI contrast agents [80,139,144] . Ostroverkhov et al immobilized a bacteriochlorin based photosensitizer on MNPs coated with human serum albumin (HSA) for use in photodynamic therapy of cancer cells.…”

Section: Imaging Applicationsmentioning

confidence: 99%